Volumetric Biotechnologies has announced its moving its HQ to the East End Maker Hub. Image courtesy of East End Maker Hub

The East End Maker Hub has landed perhaps its most intriguing tenant thus far — a Houston startup that makes 3D-printed human organs.

Volumetric Biotechnologies Inc. has leased 11,200 square feet at the East End Maker Hub to serve as its headquarters and manufacturing center. Jordan Miller, co-founder of Volumetric, says one of the benefits of being located at the hub will be access to a cleanroom operated by Alchemy Industrial, a 3D manufacturer of medical devices. Earlier this year, Houston-based Alchemy leased more than 5,400 square feet at the East End hub.

Volumetric will occupy space in the first phase of the 307,000-square-foot project East End Maker Hub. That phase of the $37 million project is set to open soon. The startup's current 5,000-square-foot headquarters is at 7505 Fannin St., near the Woman's Hospital of Texas and south of the Texas Medical Center.

Miller says Volumetric's new home will help it "maintain and accelerate our already breakneck progress." Volumetric's 12 biological, chemical, mechanical, and electrical engineers focus on producing human organs and tissues like the liver, kidney, pancreas, lung, and heart using a mix of medical-grade plastics and human cells.

"We're straining to scale our company as fast as our team is inventing and progressing our technologies. It's an absolutely wonderful problem to have," Miller says.

Volumetric hopes to commercialize its 3D-printed organs in 2021. Founded in 2018, Volumetric is a privately held spin-out of Rice University's Department of Bioengineering. It has received $1.8 million in funding, according to Crunchbase. Investors include Silicon Valley-based Sand Hill Angels, and the Springfield, Virginia-based Methuselah Foundation and Methuselah Fund.

Local Realtor Mike Pittman, a development associate with Pearland-based project partner Urban Partnerships Community Development Corp., recruited Volumetric to the hub. He says he's also working with a distillery, a coffee roaster, and a medical gown manufacturer on leasing space there.

The first phase of the East End Maker Hub is set to open soon. Image courtesy of East End Maker Hub

Once the East End Maker Hub opens, Houston's East End District will be home to the largest maker hub in Texas and one of the largest such facilities in the U.S. Being built in three phases on a 21-acre site at 6501 Navigation Blvd., the East End Maker Hub aims to create an environment that gives members of the community access to trade skills and career opportunities, and to provide businesses a place for innovation and manufacturing. The hub's second and third phases are on track to be finished in 2021.

The soon-to-open first phase will feature "white box" suites, ranging in size from 420 square feet to 20,000 square feet, that cater to three sectors:

  • Innovation (robotics, 3D printing, and R&D)
  • Crafting (ceramics, fine woodworking, and screen printing)
  • Light fabrication (food production).

Aside from Alchemy, tenants recently lined up for the hub include Houston-based Waste Management Inc., whose R&D team will occupy more than 3,500 square feet, and Houston-based construction technology company Rugged Robotics Inc., which is renting 1,700 square feet.

"We're not the place for software companies, but our innovation area is the place for hardware companies — those that are into drones, robotics, 3D printing," Pittman says.

The project's hardware innovation element could boost Houston's manufacturing economy, he says. A recent analysis by the Smartest Dollar website found that 7.5 percent of the Houston metro area's workforce is employed in manufacturing. From 1999 to 2019, the number of manufacturing jobs in Houston grew by just 1.9 percent.

So far, the nonprofit TXRX Labs makerspace is the hub's largest tenant, having signed a lease for 65,000 square feet in the first phase. TXRX Labs and Urban Partnerships Community Development teamed up to develop the hub. TXRX contributed $1.25 million in equity, and Urban Partnerships Community Development raised $35.75 million in capital.

Houston-based Stewart Builders is the general contractor for the East End Maker Hub, and Houston-based Method Architecture is the architect of record.

Aside from supplying room for businesses and nonprofits to grow, the hub seeks to provide training and jobs for local residents. Pittman says the hub — located within a tax-advantaged Opportunity Zone — encourages its tenants to hire people who live within a three-mile radius.

"You don't have to go and get a Ph.D. in nuclear science for these jobs to be able to attain really good wages for your family," he says.

Phases two and three of the hub are expected in 2021. Image courtesy of East End Maker Hub

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.